New Lens for Cataracts
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests two types of lenses, Clareon PanOptix and Clareon PanOptix Pro, used in cataract surgery to determine which is safer and more effective. Cataracts can cloud vision, and these new lenses aim to improve sight after surgery. Participants will receive a lens in each eye, one type in the first eye and the other type in the second eye, about a week apart. This trial suits those planning cataract surgery on both eyes and who have mild corneal astigmatism (less than 1.00 diopter, a measure of eye curvature). As an unphased trial, it offers a unique opportunity to explore innovative lens options for clearer vision post-surgery.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that these intraocular lenses are safe for cataract treatment?
A previous study showed that the Clareon PanOptix IOL is generally safe for patients. Fewer people reported visual issues like glare or halos six months after surgery compared to other lenses, suggesting that most people tolerate the lens well. Many patients were satisfied and achieved good vision without needing glasses.
The Clareon PanOptix Pro IOL is newer, so less information is available about it. It is designed to help patients see clearly at different distances, potentially reducing the need for glasses. As a new product, detailed safety data is still being gathered. However, it is based on the Clareon PanOptix technology, which is known to be safe.
Both lenses aim to improve vision and are generally considered safe based on current evidence. Participants considering the trial can feel reassured by the positive safety data for the Clareon PanOptix and the promising design of the Clareon PanOptix Pro.12345Why are researchers excited about this trial's treatments?
Researchers are excited about Clareon PanOptix and Clareon PanOptix Pro because these innovative lens options offer potential improvements over traditional monofocal lenses used in cataract surgeries. Unlike standard monofocal lenses that provide clear vision at just one distance, these new lenses are designed to offer a range of vision, potentially reducing the need for glasses after surgery. The Clareon lenses also utilize advanced optics and materials that may enhance visual clarity and reduce issues like halos and glare, which are common with some multifocal lenses. This could lead to a significant improvement in patients' quality of life by allowing them to see well at various distances with minimal visual disturbances.
What evidence suggests that these intraocular lenses are effective for cataracts?
This trial will compare the Clareon PanOptix and Clareon PanOptix Pro lenses for cataract surgery. Research has shown that the Clareon PanOptix lenses improve vision by reducing unwanted light reflections, which can affect sight. Studies have found that these lenses provide clear vision at various distances—far, middle, and close-up. In contrast, the Clareon PanOptix Pro lenses offer even less light scatter and make better use of available light, resulting in clearer vision with fewer visual disturbances. Both lenses are promising options for enhancing vision clarity after cataract surgery.36789
Who Is on the Research Team?
Principal Clinical Trial Lead
Principal Investigator
Alcon Research, LLC
Are You a Good Fit for This Trial?
This trial is for adults who need cataract surgery in both eyes, can follow the study schedule, and have less than 1.00 diopter of preoperative corneal astigmatism. It's not for pregnant or breastfeeding women, those wanting monovision correction, or anyone with certain eye conditions.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
CPO IOL or CPO Pro IOL is implanted in the first eye, followed by the second eye surgery 7-14 days later
Follow-up
Participants are monitored for safety and effectiveness after treatment, with primary endpoint assessed at Month 2
What Are the Treatments Tested in This Trial?
Interventions
- Clareon PanOptix
- Clareon PanOptix Pro
Trial Overview
The study compares two types of trifocal lenses: Clareon PanOptix Pro IOL and Clareon PanOptix IOL. Participants will receive one type of lens during their planned cataract surgery to see which is safer and more effective.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
CPO Pro IOL implanted in the first eye, as randomized. The fellow eye will receive CPO IOL. The second eye surgery will occur approximately 7-14 days after the first eye surgery.
CPO IOL implanted in the first eye, as randomized. The fellow eye will receive CPO Pro IOL. The second eye surgery will occur approximately 7-14 days after the first eye surgery.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Alcon Research
Lead Sponsor
Raquel C. Bono
Alcon Research
Chief Medical Officer since 2022
MD from Harvard Medical School
David Endicott
Alcon Research
Chief Executive Officer since 2018
MBA from University of Southern California
Citations
One-year outcomes of a trifocal intraocular lens with glistening ...
The Clareon PanOptix (CNWT) IOL is a newer trifocal IOL made from a glistening-free hydrophobic acrylic material incorporating hydroxyethyl ...
Clareon®️ PanOptix®️ Pro: Surgeons Share Early Insights
50% less light scatter, the lowest reported light scatter of any trifocal IOL. · Unprecedented 94% light utilization in trifocal IOLs, compared ...
The Clareon Vs AcrySof PanOptix Trifocal IOL
Significantly more AcrySof (66%) than Clareon (42%) patients achieved a spherical equivalent outcome within 0.25 D of target. Best corrected ...
Alcon Announces New Cataract Surgery Outcomes Data, ...
Data from Modi demonstrates lower instances of visual disturbances at 6 months post-op in AcrySof® IQ PanOptix IOLs, when compared to TECNIS ...
Functional Outcomes After Refractive Lens Exchange With ...
There is as yet scarce clinical data on the Clareon. PanOptix IOL, as it is relatively new. Lee et al. retrospec- tively examined outcomes after ...
Clinical and Patient-Reported Outcomes After Mix-and-Match ...
Mix-and-match implantation of the Clareon PanOptix and Vivity IOLs yields good patient satisfaction potentially by combining the advantages of ...
Functional Outcomes After Refractive Lens Exchange With ...
In a retrospective study of RLE patients implanted with the AcrySof IQ PanOptix Toric IOL Wallerstein et al found 87% of them achieved 20/20 binocular UDVA, ...
Clareon® Panoptix® IOL | Alcon Professional - MyAlcon
Effectiveness and Safety of the Clareon Monofocal Intraocular Lens: Outcomes from a 12-Month Single-Arm Clinical Study in a Large Sample.
9.
bmcophthalmol.biomedcentral.com
bmcophthalmol.biomedcentral.com/articles/10.1186/s12886-025-04198-2One-year outcomes of a trifocal intraocular lens with glistening ...
The new hydrophobic acrylic trifocal IOL (CNWT) with HEMA demonstrated significant improvements in visual acuity and stable refractive outcomes over one year ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.